Table 3.
Characteristics of patients with bleeding or thromboembolic event (TE) and patients without.
| With bleeding (N = 21) | Without bleeding (N = 41) | p | With TE (N = 4) | Without TE (N = 58) | p | |
|---|---|---|---|---|---|---|
| Apixaban dose (5 mg/2.5 mg) | 12/9 | 20/21 | 0.73 | 1/3 | 31/27 | 0.56 |
| Age (years) | 79 ± 6 | 77 ± 9 | 0.64 | 85 ± 3 | 77 ± 8 | 0.03 |
| CHA2DS2VASc score | 3.9 ± 1.3 | 4.1 ± 1.7 | 0.58 | 5.3 ± 0.5 | 3.9 ± 1.5 | 0.07 |
| HAS-BLED score | 1.3 ± 0.6 | 1.0 ± 0.5 | 0.03 | 1.8 ± 0.5 | 1.0 ± 0.5 | 0.03 |
| LC–MS/MS trough (ng/mL) | 96 (78–160) | 101 (83–135) | 0.98 | 91 (81–103) | 103 (82–140) | 0.44 |
| CV trough (%) | 18 ± 12 | 22 ± 16 | 0.37 | 22 ± 10 | 20 ± 15 | 0.56 |
| LC–MS/MS peak (ng/mL) | 221 (163–309) | 211 (169–255) | 0.54 | 153 (149–169) | 219 (167–283) | 0.05 |
| CV peak (%) | 19 ± 13 | 21 ± 10 | 0.43 | 25 ± 8 | 20 ± 11 | 0.23 |
| Berichrom Heparin anti-Xa trough (ng/mL) | 89 (76–152) | 97 (78–119) | 1.00 | 90 (78–99) | 96 (77–133) | 0.50 |
| Berichrom Heparin anti-Xa peak (ng/mL) | 184 (158–247) | 180 (155–209) | 0.43 | 152 (129–170) | 184 (158–220) | 0.09 |
| STA–Liquid anti-Xa trough (ng/mL) | 77 (63–121) | 80 (67–98) | 0.97 | 74 (63–81) | 80 (64–111) | 0.74 |
| STA–Liquid anti-Xa peak (ng/mL) | 192 (136–238) | 180 (155–209) | 0.19 | 131 (116–140) | 170 (135–209) | 0.09 |
Results are shown as number of cases, average ± SD or median with first to third quartile.
CV oefficient of variation.